The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Companies are responding to patent cliffs and the increased cost of research and development for more complex products.

GSK has agreed to acquire full global rights to a potential best-in-class trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million, expanding the pharmaceutical ...

GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens ...

GSK said on Tuesday it had agreed a deal worth up to $750 million ​to buy a trispecific T cell-engager (TCE), a drug ‌designed to help T-cells target cancer, from China-based biotechnology firm ...

GSK (NYSE:GSK) is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost ...

GSK Plc agreed another deal with British biotech Relation Therapeutics Ltd. to use artificial intelligence to speed up drug development. The agreement, which could see Relation paid up to $110 million ...

GSK reported 5% year-over-year revenue growth at constant currency and a 33.3% core operating margin. Management reaffirmed full-year guidance and announced a three-year restructuring program to cut ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The three-year plan will cost ...

GSK Plc plans annual savings of £1.9 billion ($2.5 billion) by 2029, as the drugmaker invests more in its pipeline to replace revenue from the looming patent expiry of an HIV medicine. The cuts will ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Half a year into taking ...